Immediate Impact
34 standout
Citing Papers
Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
2025 Standout
Integrating artificial intelligence with mechanistic epidemiological modeling: a scoping review of opportunities and challenges
2025 Standout
Works of Teja Thorat being referenced
Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosis
2024
A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted
2016
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Teja Thorat | 252 | 71 | 126 | 27 | 460 | |
| Nancy J.W. Lewis | 218 | 49 | 138 | 18 | 543 | |
| Rami Z. Morsi | 116 | 38 | 79 | 36 | 417 | |
| Friedrich Wittenbecher | 186 | 29 | 204 | 16 | 547 | |
| Bryony Dawkins | 194 | 37 | 179 | 23 | 554 | |
| Edward C. Mansley | 197 | 48 | 81 | 22 | 444 | |
| Sheela Upadhyaya | 165 | 42 | 76 | 24 | 416 | |
| Hye-Young Kwon | 289 | 43 | 57 | 50 | 523 | |
| Arnold V. Hurtado | 181 | 21 | 219 | 15 | 573 | |
| Chiara Whichello | 246 | 9 | 137 | 25 | 415 | |
| George J Joseph | 104 | 16 | 65 | 25 | 526 |
All Works
Login with ORCID to disown or claim papers
Loading papers...